NCT04323657View on ClinicalTrials.gov

TC-110 T Cells in Adults With Relapsed or Refractory Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

March 27, 2020

Primary Completion Date

February 24, 2023

Study Completion Date

February 24, 2023

Conditions
Non Hodgkin LymphomaAcute Lymphoblastic LeukemiaDiffuse Large B Cell LymphomaPrimary Mediastinal Large B Cell LymphomaMantle Cell LymphomaFollicular Lymphoma
Interventions
DRUG

TC-110 T Cells

TC-110 T Cells

DRUG

Fludarabine

Flu/Cy Lymphodepletion

DRUG

Cyclophosphamide

Flu/Cy Lymphodepletion

Trial Locations (3)

37203

Sarah Cannon Research Institute, Nashville

77030

University of Texas MD Anderson Cancer Center, Houston

80218

Colorado Blood Cancer Institute, Denver

Sponsors

Lead Sponsor

TCR2 Therapeutics
All Listed Sponsors
lead

TCR2 Therapeutics

INDUSTRY